Abstract:Tuberculosis (TB) is an ancient infectious disease. Before the availability of effective drug therapy, it had high morbidity and mortality. In the past 100 years, the discovery of revolutionary anti-TB drugs such as streptomycin, isoniazid, pyrazinamide, ethambutol and rifampicin, along with drug combination treatment, has greatly improved TB control globally. As anti-TB drugs were widely used, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of emerged due to acquired genetic mutations, and this now presents a major problem for effective treatment. Genes associated with drug resistance have been identified, including mutations in isoniazid resistance, mutations in rifampin resistance, mutations in pyrazinamide resistance, and mutations in quinolone resistance. The major mechanisms of drug resistance include loss of enzyme activity in prodrug activation, drug target alteration, overexpression of drug target, and overexpression of the efflux pump. During the disease process, may reside in different microenvironments where it is expose to acidic pH, low oxygen, reactive oxygen species and anti-TB drugs, which can facilitate the development of non-replicating persisters and promote bacterial survival. The mechanisms of persister formation may include toxin-antitoxin (TA) modules, DNA protection and repair, protein degradation such as trans-translation, efflux, and altered metabolism. In recent years, the use of new anti-TB drugs, repurposed drugs, and their drug combinations has greatly improved treatment outcomes in patients with both drug-susceptible TB and MDR/XDR-TB. The importance of developing more effective drugs targeting persisters of is emphasized. In addition, host-directed therapeutics using both conventional drugs and herbal medicines for more effective TB treatment should also be explored. In this article, we review historical aspects of the research on anti-TB drugs and discuss the current understanding and treatments of drug resistant and persistent tuberculosis to inform future therapeutic development.

Defensins: The Case For Their Use Against Mycobacterial Infections

Defensins: A novel weapon against Mycobacterium tuberculosis ?

In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis

Recent advances in the research and development of human defensins.

[Advances in the Research of Human Defensins].

Synergistic role of Mycobacterium indicus pranii and Human Beta Defensin-2 as adjunctive therapy against Mycobacterium tuberculosis

The past, present and future of tuberculosis treatment.

Defensins: The natural peptide antibiotic

Defensins and sepsis.

Regulatory Role of Defensins in Inflammatory Bowel Disease

Defensins and Sepsis

Antimicrobial Activity of Recombinant Mature Bovine Neutrophil Β-Defensin 4 on Mycobacterial Infection.

PP-003 Evaluation on the cellular immunity of M. tuberculosis in HIV/AIDS and tuberculosis co-infected individuals in China

Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents

Mycobacterium tuberculosis proteases and implications for new antibiotics against tuberculosis.

Mechanisms and regulation of defensins in host defense

Defensins: A Double-Edged Sword in Host Immunity

Antimycobacterial Activity of Pichia Pastoris-Derived Mature Bovine Neutrophil Β-Defensins 5.

Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis

Expressions of Antimicrobial Peptides LL-37, Human Beta Defensin-2 and -3 in the Lesions of Cutaneous Tuberculosis and Tuberculids